{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:29:27Z","timestamp":1761092967920,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.urolonc.2008.11.002","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T05:06:28Z","timestamp":1232687188000},"page":"585-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Friend or foe? Role of peroxisome proliferator-activated receptor-\u03b3 in human bladder cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Teruo","family":"Inamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2008.11.002_bib1","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.urolonc.2008.11.002_bib2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","article-title":"Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium","volume":"100","author":"Dreicer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2008.11.002_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2008.11.002_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00006676-200411000-00002","article-title":"COX and PPAR: Possible interactions in pancreatic cancer","volume":"29","author":"Eibl","year":"2004","journal-title":"Pancreas"},{"key":"10.1016\/j.urolonc.2008.11.002_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/ijc.22582","article-title":"EP1-4 subtype, COX, and PPAR \u03b3 receptor expression in colorectal cancer in prediction of disease-specific mortality","volume":"121","author":"Gustafsson","year":"2007","journal-title":"Int Journal Cancer"},{"key":"10.1016\/j.urolonc.2008.11.002_bib6","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1128\/MCB.01617-06","article-title":"Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor \u03b3 1 phosphorylation","volume":"28","author":"Johnstone","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib7","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/carcin\/bgl001","article-title":"Peroxisome proliferator-activated receptor (PPAR) \u03b3 gene polymorphisms and colorectal cancer risk among Chinese in Singapore","volume":"27","author":"Koh","year":"2006","journal-title":"Carcinogenesis"},{"issue":"Suppl 4","key":"10.1016\/j.urolonc.2008.11.002_bib8","first-page":"595","article-title":"The expression of PPAR \u03b3 in gastric cancer","volume":"59","author":"Morita","year":"2001","journal-title":"Nippon Rinsho"},{"key":"10.1016\/j.urolonc.2008.11.002_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1349-7006.2003.tb01443.x","article-title":"PPAR \u03b3 ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells","volume":"94","author":"Nagamine","year":"2003","journal-title":"Cancer science"},{"key":"10.1016\/j.urolonc.2008.11.002_bib10","first-page":"582","article-title":"The PPAR-\u03b3 agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines","volume":"4","author":"Radhakrishnan","year":"2005","journal-title":"Cell cycle (Georgetown)"},{"key":"10.1016\/j.urolonc.2008.11.002_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9765-7","article-title":"MAZ drives tumor-specific expression of PPAR \u03b3 1 in breast cancer cells","volume":"111","author":"Wang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.urolonc.2008.11.002_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s000110050622","article-title":"Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation","volume":"49","author":"Chinetti","year":"2000","journal-title":"Inflamm Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4757-2670-1_14","article-title":"Dietary fat, genes, and human health","volume":"422","author":"Jump","year":"1997","journal-title":"Advances in experimental medicine and biology"},{"key":"10.1016\/j.urolonc.2008.11.002_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/187152006776930891","article-title":"Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: Topical therapeutic strategies targeting COX-2 expression and activity","volume":"6","author":"Telliez","year":"2006","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","article-title":"Antineoplastic effects of peroxisome proliferator-activated receptor \u03b3 agonists","volume":"5","author":"Grommes","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib16","first-page":"397","article-title":"PPAR trilogy from metabolism to cancer","volume":"7","author":"Nahle","year":"2004","journal-title":"Curr Opin Clin Nutr Metabolic Care"},{"key":"10.1016\/j.urolonc.2008.11.002_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4161\/cbt.4.7.2014","article-title":"PPAR\u03b3 as a therapeutic target for tumor angiogenesis and metastasis","volume":"4","author":"Panigrahy","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.urolonc.2008.11.002_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/toxsci\/kfj062","article-title":"The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR)","volume":"90","author":"Peraza","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.urolonc.2008.11.002_bib19","first-page":"465","article-title":"Can PPAR\u03b3 ligands be used in cancer therapy?","volume":"4","author":"Rumi","year":"2004","journal-title":"Cur Med Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.pharmtox.40.1.491","article-title":"Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators","volume":"40","author":"Corton","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib21","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1101\/gad.10.8.974","article-title":"Differential activation of adipogenesis by multiple PPAR isoforms","volume":"10","author":"Brun","year":"1996","journal-title":"Genes Dev"},{"key":"10.1016\/j.urolonc.2008.11.002_bib22","first-page":"977","article-title":"Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells","volume":"28","author":"Murad","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib23","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1101\/gad.11.15.1987","article-title":"PPAR\u03b3 induces cell cycle withdrawal: Inhibition of E2F\/DP DNA-binding activity via down-regulation of PP2A","volume":"11","author":"Altiok","year":"1997","journal-title":"Genes Dev"},{"key":"10.1016\/j.urolonc.2008.11.002_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/00001813-200410000-00008","article-title":"Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111","volume":"15","author":"Budman","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.urolonc.2008.11.002_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/1535-7163.247.3.3","article-title":"A new class of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3\u2032-indolyl)-1-(p-substituted phenyl)methanes","volume":"3","author":"Qin","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2008.11.002_bib26","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1054\/bjoc.2000.1457","article-title":"Expression of peroxisome proliferator-activated receptor (PPAR)\u03b3 in gastric cancer and inhibitory effects of PPAR\u03b3 agonists","volume":"83","author":"Sato","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2008.11.002_bib27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ijc.10980","article-title":"Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists","volume":"104","author":"Yoshimura","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2008.11.002_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/pros.10058","article-title":"Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer","volume":"51","author":"Segawa","year":"2002","journal-title":"The Prostate"},{"key":"10.1016\/j.urolonc.2008.11.002_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jcp.20676","article-title":"PPAR\u03b3-regulated tight junction development during human urothelial cytodifferentiation","volume":"208","author":"Varley","year":"2006","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0306-3623(01)00116-1","article-title":"The role of peroxisome proliferator-activated receptor \u03b3 in bladder cancer in relation to angiogenesis and progression","volume":"35","author":"Possati","year":"2000","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0002-9440(10)61730-0","article-title":"Role of peroxisome proliferator-activated receptor \u03b3 and its ligands in non-neoplastic and neoplastic human urothelial cells","volume":"159","author":"Nakashiro","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.neo.7900050","article-title":"Expression of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) in human transitional bladder cancer and its role in inducing cell death","volume":"1","author":"Guan","year":"1999","journal-title":"Neoplasia (New York)"},{"key":"10.1016\/j.urolonc.2008.11.002_bib33","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1126\/science.289.5483.1357","article-title":"PAX8-PPAR\u03b31 fusion oncogene in human thyroid carcinoma [corrected]","volume":"289","author":"Kroll","year":"2000","journal-title":"Science (New York)"},{"key":"10.1016\/j.urolonc.2008.11.002_bib34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1097-2765(01)80012-5","article-title":"Loss-of-function mutations in PPAR \u03b3 associated with human colon cancer","volume":"3","author":"Sarraf","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.urolonc.2008.11.002_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/0008-5472.CAN-03-2556","article-title":"Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor \u03b3","volume":"64","author":"Badawi","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib36","first-page":"5671","article-title":"A new ligand for the peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3), GW7845, inhibits rat mammary carcinogenesis","volume":"59","author":"Suh","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib37","first-page":"2424","article-title":"Ligands for peroxisome proliferator-activated receptors alpha and \u03b3 inhibit chemically induced colitis and formation of aberrant crypt foci in rats","volume":"61","author":"Tanaka","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1349-7006.2001.tb01108.x","article-title":"Troglitazone, a ligand for peroxisome proliferator-activated receptor \u03b3, inhibits chemically-induced aberrant crypt foci in rats","volume":"92","author":"Kohno","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib39","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/2036","article-title":"Activation of the peroxisome proliferator-activated receptor \u03b3 promotes the development of colon tumors in C57BL\/6J-APCMin\/+ mice","volume":"4","author":"Lefebvre","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2008.11.002_bib40","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/2042","article-title":"Activators of the nuclear receptor PPAR\u03b3 enhance colon polyp formation","volume":"4","author":"Saez","year":"1998","journal-title":"Nat Medicine"},{"key":"10.1016\/j.urolonc.2008.11.002_bib41","doi-asserted-by":"crossref","first-page":"17830","DOI":"10.1074\/jbc.M200186200","article-title":"Loss of the peroxisome proliferation-activated receptor \u03b3 (PPAR\u03b3) does not affect mammary development and propensity for tumor formation but leads to reduced fertility","volume":"277","author":"Cui","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib42","doi-asserted-by":"crossref","first-page":"48950","DOI":"10.1074\/jbc.M108722200","article-title":"15-Deoxy-\u03b412,14-prostaglandin J2 and thiazolidinediones activate the MEK\/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells","volume":"276","author":"Takeda","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000065303","article-title":"Activation of peroxisome proliferator-activated receptor-107 inhibits apoptosis induced by serum deprivation in LLC-PK1 cells","volume":"10","author":"Haraguchi","year":"2002","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib44","doi-asserted-by":"crossref","first-page":"31781","DOI":"10.1074\/jbc.M204279200","article-title":"Thiazolidinedione activation of peroxisome proliferator-activated receptor \u03b3 can enhance mitochondrial potential and promote cell survival","volume":"277","author":"Wang","year":"2002","journal-title":"J Biol Chemistry"},{"key":"10.1016\/j.urolonc.2008.11.002_bib45","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib46","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/0008-5472.CAN-05-2755","article-title":"Inhibition of bladder tumor growth by 1,1-bis(3>29>-indolyl)-1-(p-substituted phenyl) methanes: A new class of peroxisome proliferator-activated receptor \u03b3 agonists","volume":"66","author":"Kassouf","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib47","doi-asserted-by":"crossref","first-page":"23534","DOI":"10.1074\/jbc.M200172200","article-title":"Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells","volume":"277","author":"Fauconnet","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib48","doi-asserted-by":"crossref","first-page":"19761","DOI":"10.1074\/jbc.270.34.19761","article-title":"Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells","volume":"270","author":"Ikeda","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib49","first-page":"5281","article-title":"Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer","volume":"57","author":"Crew","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000020170","article-title":"What is the optimal regimen for BCG intravesical therapy?","volume":"37","author":"Zlotta","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib51","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/ncpuro0559","article-title":"A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer","volume":"3","author":"Kamat","year":"2006","journal-title":"Nat Clin Pract"},{"key":"10.1016\/j.urolonc.2008.11.002_bib52","first-page":"1697","article-title":"Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1, and TIS)","volume":"162","author":"Smith","year":"1999","journal-title":"Am Urol Assoc, J Urol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib54","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib55","first-page":"269","article-title":"Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor \u03b3 in bladder cancer cells","volume":"17","author":"Lodillinsky","year":"2006","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.urolonc.2008.11.002_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/jaut.2002.0609","article-title":"NKT cell defects in NOD mice suggest therapeutic opportunities","volume":"19","author":"Kukreja","year":"2002","journal-title":"J Autoimmune"},{"key":"10.1016\/j.urolonc.2008.11.002_bib57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/jaut.1999.0281","article-title":"Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2, and IA-2\u03b2 predict immune-mediated (type 1) diabetes in relatives","volume":"12","author":"Maclaren","year":"1999","journal-title":"J Autoimmune"},{"key":"10.1016\/j.urolonc.2008.11.002_bib58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/carcin\/19.1.49","article-title":"The nuclear eicosanoid receptor, PPAR\u03b3, is aberrantly expressed in colonic cancers","volume":"19","author":"DuBois","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2008.11.002_bib59","doi-asserted-by":"crossref","first-page":"29681","DOI":"10.1074\/jbc.M103779200","article-title":"Target genes of peroxisome proliferator-activated receptor \u03b3 in colorectal cancer cells","volume":"276","author":"Gupta","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib60","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib61","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1517\/13543784.12.12.1925","article-title":"Therapeutic potential of thiazolidinediones as anticancer agents","volume":"12","author":"Panigrahy","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.urolonc.2008.11.002_bib62","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V58.6.1159.1159","article-title":"Somatic cell hybrid analyses of hematopoietic differentiation","volume":"58","author":"Koeffler","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2008.11.002_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc1254","article-title":"Peroxisome-proliferator-activated receptors and cancers: Complex stories","volume":"4","author":"Michalik","year":"2004","journal-title":"Nat Rev"},{"key":"10.1016\/j.urolonc.2008.11.002_bib64","first-page":"239","article-title":"Peroxisome proliferator activated receptor-\u03b3 ligands as potent antineoplastic agents","volume":"3","author":"Theocharisa","year":"2003","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.urolonc.2008.11.002_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.94.1.237","article-title":"Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor \u03b3 and the retinoid X receptor","volume":"94","author":"Tontonoz","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urolonc.2008.11.002_bib66","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0016-5085(98)70072-1","article-title":"Activation of PPAR\u03b3 leads to inhibition of anchorage-independent growth of human colorectal cancer cells","volume":"115","author":"Brockman","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.urolonc.2008.11.002_bib67","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","article-title":"Ligands for peroxisome proliferator-activated receptor \u03b3 and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice","volume":"95","author":"Elstner","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urolonc.2008.11.002_bib68","first-page":"3344","article-title":"Ligand for peroxisome proliferator-activated receptor \u03b3 (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo","volume":"58","author":"Kubota","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2008.11.002_bib69","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/2030","article-title":"Differentiation and reversal of malignant changes in colon cancer through PPAR\u03b3","volume":"4","author":"Sarraf","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2008.11.002_bib70","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/mol.105.012260","article-title":"Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: An example of nongenomic signaling","volume":"68","author":"Gardner","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.urolonc.2008.11.002_bib71","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4161\/cc.3.11.1210","article-title":"PPAR\u03b3 signaling: One size fits all?","volume":"3","author":"Jain","year":"2004","journal-title":"Cell Cycle (Georgetown)"},{"key":"10.1016\/j.urolonc.2008.11.002_bib72","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim Biophys Acta"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814390800327X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814390800327X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:55:01Z","timestamp":1761040501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814390800327X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S107814390800327X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.11.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Friend or foe? Role of peroxisome proliferator-activated receptor-\u03b3 in human bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2008.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}